
West Pharmaceutical Services guidance
$418.17+0.09%Close 17 Nov 2026 · Market value $28.97B
In its results release of 29 Oct 2026 (Q3 FY2026), West Pharmaceutical Services gave 2 forecasts in figures, among them EPS (adjusted) of $9.38 to $9.48 for FY2026. Over the last two years, results landed above the company's own last range 10 of 13 times, within it 2 and below it 1.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q3 FY2026 results, 29 Oct 2026
| Measure | Period | Guidance | As stated |
|---|
| EPS · Adjusted · Raised | FY2026 | $9.38 to $9.48 | The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $9.38 to $9.48, up from the previous range of $8.85 to $9.05. |
|---|
| Capital expenditures | FY2026 | $215M to $220M | Full-year 2026 capital spending guidance is updated to a range of $215 million to $220 million, down from the prior range of $250 million to $275 million. |
|---|
Source: the company's earnings release.
Guidance against results above 10 · within 2 · below 1
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Revenue | FY2026 | $3.35B to $3.38B | Raised once | — | To come |
|---|
| Revenue growth | FY2026 | +8.8% to +10% | Raised once | — | To come |
|---|
| Organic revenue growth | FY2026 | +10% to +11% | Raised once | — | To come |
|---|
| EPS · Adjusted | FY2026 | $9.38 to $9.48 | Raised 3 times | — | To come |
|---|
| Capital expenditures | FY2026 | $215M to $220M | Lowered once | — | To come |
|---|
| Revenue | Q3 FY2026 | $820M to $835M | Given once | $875M | Above the range |
|---|
| Revenue growth | Q3 FY2026 | +1.9% to +3.8% | Given once | +8.69% | Above the range |
|---|
| EPS · Adjusted | Q3 FY2026 | $2.14 to $2.24 | Given once | $2.66 | Above the range |
|---|
| Revenue | Q2 FY2026 | $830M to $850M | Given once | $872M | Above the range |
|---|
| Revenue growth | Q2 FY2026 | +8.3% to +10.9% | Given once | +13.8% | Above the range |
|---|
| EPS · Adjusted | Q2 FY2026 | $2.05 to $2.12 | Given once | $2.37 | Above the range |
|---|
| Revenue | Q1 FY2026 | $770M to $790M | Given once | $845M | Above the range |
|---|
| EPS · Adjusted | Q1 FY2026 | $1.65 to $1.70 | Given once | $2.13 | Above the range |
|---|
| Revenue | FY2025 | $2.94B to $2.98B | Raised once | $3.07B | Above the range |
|---|
| Revenue growth | FY2025 | +5.8% to +6.1% | Given once | +6.25% | Above the range |
|---|
| Capital expenditures | FY2025 | $275M | Given once | $286M | Above the range |
|---|
| Tax rate | FY2025 | About 21% | Lowered once | 20.24% | Below the range |
|---|
| Revenue growth | Q4 FY2025 | +5.5% to +6.8% | Given once | +7.51% | Above the range |
|---|
| EPS · Adjusted | Q4 FY2025 | $1.81 to $1.86 | Given once | $2.04 | Above the range |
|---|
| Tax rate | Q4 FY2025 | About 21% | Given once | 20.62% | Within the range |
|---|
| Revenue | FY2024 | $2.88B to $2.90B | Given once | $2.89B | Within the range |
|---|
| Tax rate | Q4 FY2024 | 22% | Given once | 22.32% | Above the range |
|---|
WST in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.